MITROFLOW AORTICPERICARDIAL HEART VALVEModel 12INSTRUCTIONS FOR USEENG - PDF document

MITROFLOW AORTICPERICARDIAL HEART VALVEModel 12INSTRUCTIONS FOR USEENGLISHCAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician.SYMBOL LEGENDJ\ INSTRUCTIONS / WARNINGS: SEE MANUALjSWJETj CONTENTS STERILIZED USING ASEPTIC PROCESSING TECHNIQUE2 USE BY'.C1 5-C STORE BETWEEN 50C AND 250CSINGLE USE ONLYDO NOT RESTERILIZEREF CATALOGUE NUMBERFS-N] SERIAL NUMBERFSIZE SIZEMANUFACTURED BYQUANTITY INCLUDED IN PACKAGE© DO NOT USE IF PACKAGE IS DAMAGEDThese instructions contain important information on the use of the Mitroflow Aortic Pericardial Heart Valve andaccessories. All personnel responsible for the storage, handling and implantation of the valve are advised to readand understand this information prior to use of the Mitroflow Aortic Pericardial Heart Valve (Mitroflow valve).DEVICE DESCRIPTIONThe Mitroflow valve consists of a single piece of bovine pericardium that is preserved with glutaraldehyde andsewn onto a polyester cover

ed polymer stent. A radiopaque, silicone sewing ring is attached to the outer perimeterof the inflow side of the valve,The valves are sterilized using glutaraldehyde/formaldehyde based liquid chemical sterilants, and are packaged ina sealed plastic jar containing sterile 4% formaldehyde storage solution.The Mitroflow valve is available in aortic sizes 19, 21, 23, 25, and 27mm diameters.INDICATIONSThe Mitroflow Aortic Pericardial Heart Valve is intended for the replacement of diseased, damaged, ormalfunctioning native or prosthetic aortic valves.CONTRAINDICATIONSThere are no known contraindlications for the use of the Mitroflow valve.-C -2-WARNINGS AND PRECAUTIONS* Clinical experience described in the medical literature suggests that juvenile patients or patients who areundergoing chronic hemodialysis, who have parathyroid disease or impaired calcium metabolism, or whoare 55 years of age or less may experience accelerated calcification of bioprosthetic heart

valves.* FOR SINGLE USE ONLY* Prior to opening the valve container, inspect the high and low temperature indicators on the valve carton foractivation. Do not use the valve if either the high or low temperature indicators have been activated (Seesection DIRECTIONS FOR USE).* All persons responsible for the handling and preparation of the valve for implantation must exercise utmostcare to avoid damage to the valve, tissue, stent, and fabric.• Do not pass any transvalvular diagnostic catheters or transarterial pacing leads through the in situbioprosthesis. These procedures may cause damage to the valve.Warnings Prior to UseDo not use the Mitrofiow valve:* If the expiration date has elapsed* If either the high or low temperature indicators in the valve carton have been activated* If the valve container is damaged or has leaked* If the tamper evident seal is broken* If the bioprosthesis has been damaged* If the storage solution does not completely cover the val

veSterilization* The Mitroflow valve cannot be resterilized. The valve container should never be subjected to sterilizationprocedures involving moist heat, ethylene oxide, chemical sterilants, or irradiation.* The valve identification tag is not a sterility indicator.* The Mitroflow reusable valve handles and aortic obturators must be cleaned and sterilized prior to use.Precautions During Use*The exterior of the valve container is non-sterile and should not be introduced into the sterile field.*Once the tamper evident seal on the valve container is broken, the Mitroflow valve should be usedimmediately or contact your local sales representative to make arrangements for return or replacement.*Do not allow the valve tissue to dry. Upon removal of the valve from the valve container, immediately placethe valve in sterile physiological saline for rinsing.*Adequate rinsing with sterile physiological saline is mandatory before implantation to reduce theformaldehyde

concentration (see section DIRECTIONS FOR USE). No other solutions, drugs, chemicals,antibiotics, etc. should be added to the rinse solution as irreparable damage to the valve, which may not beapparent under visual inspection, may result,*All persons responsible for the handling and preparation of the valve for implantation must exercise utmostcare to avoid damage to the valve, tissue, stent, and fabric,*Extreme care should be exercised when placing sutures through the sewing ring to avoid possible laceration ofthe tissue. IF A VALVE IS DAMAGED, THE VALVE MUST BE EXPLANTED AND REPLACED.*Use only the Mitroflow obturators. Use of other obturators or other sizing techniques may result in misleadingvalve sizing information.ADVERSE EVENTSThe clinical investigation of the Mitroflow Aortic Pericardial Heart Valve supports the safety of the Mitroflowvalve. Table I presents the adverse event rates as observed in the clinical investigation. -3-Table I. Observed Adve

rse Event Rates -Total Patients: N = 699, Cumulative follow-up 835.9 patient-years.Early Events]Late Events2Percent Freedom From Event [SE]3% ofAdverse event Pain n 0/%/Pt-Yr 1 Year 2 YearsPatientsAll mortality 31 4.4 80 10.24 85.0 [1.4] 81.4 [1.8]Valve-related death(includesreldden death) 2 0.3 18 2.30 96.7 [0.7] 96.7 [0.7](includes sudden death)Structural valve deterioration 0 0 2 0.26 99.8 [0.2] 99.4 [0.4]All Anticoagulant-related bleeding 12 1.7 14 1.79 96.4 [0.7] 95.5 [1.01Major Anticoagulant-related bleeding 6 0.9 7 0.90 98.3 [0.5] 97.4 [0.81Thromboembolism 17 2.4 15 1.92 95.1 [0.9] 94.7 [0.9]Major thromboembolic event 6 0.9 6 0.77 98.2 [0.6] 97.8 [0.7]Valve Thrombosis 0 0 0 0 100 [0] 100 [0]Endocarditis 1 0.1 19 2.43 96.8 [0.7] 96.4 [0.8]Non-structural valve dysfunction44 0.6 6 0.77 98.6 [0.5] 98.2 [0.6]Perivalvular Leak 4 0.6 4 0.51 98.7 [0.41 98.7 [0.4]Hemolysis 0 0 0 0 100 [0] 100 [0]Reoperation (including explant) 0 0 9 1.15 98.5 [0.5] 98.5 [0.51

Explant 0 0 8 1.02 98.7 [0.5] 98.7 [0.5]Early death occurred within 30 days of implant, and includes intraoperative deaths. Early valve-related events includepostoperative events occurring 1-30 days post implant. Early event rates calculated as the percentage of patients with an event.Late postoperative events �(30 days post implant). Late event rates calculated as linearized hazard rates (0/a/patient-year).Calculations for linearized rates were based on 781.1 late patient-years.3Freedom from first event (early or late) rates were calculated using the Kaplan-Meier method. SE -Standard error.4Includes perivalvular leaks (8), and residual aortic stenosis (1) or insufficiency (1).Potential Adverse EventsAdverse events potentially associated with the use of bioprosthetic heart valves (in alphabetical order) include (butmay not be limited to):* Angina ·Structural valve deterioration• Cardiac arrhythmias * Intrinsic and extrinsic mineralization* Endocardit

is (calcification)* Heart failure ·Leaflet perforation or tear* Hemolysis Leaflet rupture* Hemolytic anemia * Thromboembolism* Hemorrhage * Valve thrombosis* Leak, transvalvular or perivalvular* Myocardial infarctionIt is possible that these complications could* Non-structural dysfunction lead to:* Inappropriate sizing * Reoperation* Leaflet entrapment by tissue in-growth * Explant* Prosthesis regurgitation * Permanent disability* Prosthesis stenosis* Death* Suture entrapment on commissures* Stroke -4-While these complications have not been observed in the majority of patients after cardiac valve replacement, thesurgeon should carefully weigh the potential of such an adverse event in selecting the optimum valve replacementfor each patient.CLINICAL STUDYA prospective, non-randomized, multicenter clinical study was conducted on 699 patients requiring isolated aorticvalve replacement (AVR) with the Mitroflow Aortic Pericardial Heart valve. Cumulative follow-up

of the studycohort was 835.9 patient-years, with mean follow-up of 14.4 months. The patients underwent AVR betweenNovember 2003 and December 31, 2005 at 25 centers (28 hospitals) in the United States (20 centers) and Canada (5centers).In the study population, there were 397 (56.8 %) males and 302 (43.2%) females with a mean age at implant of 74.3years and an age range of 27 to 93 years. The primary indications for valve replacement were calcification 93.6%,congenital anomalies 13.7%, rheumatic heart disease 4.1%, and previous valve implant 1.4%. Follow-up methodsused included hospital visits or clinic visits.Table 2 presents by valve size, the mean gradients, effective orifice area, and valve regurgitation as reported inechocardiograms performed on patients in the study population.Table 2. Effectiveness Outcomes, Hemod mic Results' at 1 Year: Isolated AVR (N = 544).Hemodynamic Data Valve Size219 (N334) 21 (N=143) 23 (N=193) 25 (N=128) 27 (N=42)Mean gradien

t (mmnHg) n4=33 n=136 n= 189 n=122 n=39Mean + SD 13.4±5.0 11.4±+4.4 10.5±+4.2 8.7_±3.3 7.4_±2.7Effective orifice area (cm2) n=30 n:I31 nA85 nl2l n37Mean_± SD 1.1 ±+0.2 1.2 ±0.3 1.4:±-0.3 1.6_±0.3 1.8±0.3Regurgitation n=34 n=143 n=193 n=128 n=42None 21 (61.8%) 103 (72.0%) 145 (75.1%) 98 (76.6%) 33 (78.6%)Trace 8(23.5%) 18(12.6%) 35(18.1%) 22(17.2%) 4(9.5%)Mild 4 (11.8%) 20 (14.0%) 13 (6.7%) 6 (4.7%) 5 (11.9%)Moderate 1 (2.9%) 1 (0.7%) 0 (0.0%) 2 (1.6%) 0 (0.0%)Severe 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)Not Reported 0 (0.0%) 1 (0.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%)Hemodynamic evaluation performed using transthoracic echocardiography.2Size 29mm valves were studied but data for this size are not included in this table because of the limited clinical data availableat the time of PMA evaluation.N total patients with echo evaluation in each valve size.4n = patients in each valve size with valid measurement of hemodynamic parameter.Information on preoperative an

d postoperative NYHA Functional Classification was gathered on all study patients.At their 3-6 month follow up 97.6% of patients were in NYHA Class 1/Il compared to 47.2% in preoperative NYHAClass I/II (Table 3). At 12 months 98.6% of the patients were in NYHA Class 1/11. At 2 years 97.6% were in Class1/11.-235 -5-Table 3. NYHA Functional Classifications.Preoperative Postoperative AssessmentsNYHA Class (N=692j ~~~~3-6 months 1 year 2 yearsNYHA Class (N-692)__ __N=571 ___N(N=24n ~ ~ ~~~n %n % n1 62 9.0 431 75.1 427 78.5 188 76.71I 264 38.2 129 22.5 109 20.0 5 1 20.8III ~~~~~300 43.4 II1 1.9 6 1.1 6 2.4IV 66 9.5 3 0.5 2 0O4 0 0.0N =total number of patients with NYHA evaluation at each postoperative assessment.2 n -number of patients in each NYH-A category.INDIVIDUALIZATION OF TREATMENTAnticoagulant and/or Antiplatelet TherapyExtensive published data indicates that some form of anticoagulant and/or antiplatelet therapy may be beneficialafter cardiac valve repl

acement with a bioprosthesis to reduce the risk of valve thrombosis and/or thromboembolicphenomenon.In general, for bioprostheses, anticoiagulation therapy is recommended for 90 days after aortic valve replacement.Indefinite therapy with low dose aspirin, unless contraindicated, is recommended for all patients with bioprostheticvalves. Indefinite anticoagulation therapy, unless contraindlicated, is recommended for patients with thethromboembolism risk factors of moderate to severe atria] wall calcification or other atrial wall abnormalities, atrialfibrillation, left ventricular dysfunction, a hypercoagulable condition, or a prior history of thromboembolic events,consideration should be given to prescribing indefinite anticoagulation therapy,Specific Patient PopulationsClinical experience described in the medical literature suggests that juvenile patients or patients who are undergoingchronic hemodialysis, who have parathyroid disease or impaired calcium met

abolism, or who are 55 years of age orless may experience accelerated calcification of bioprosthetic heart valves. Risks and benefits of usingglutaraldehyde-preserved bioprosthesis in these patients should be carefully weighed by the physician whenselecting the appropriate valve replacement for patients with one or more of the above factors.The medical literature indicates that children who undergo heart valve replacement may require subsequent valvereplacement procedures as a result of normal cardiac tissue development.PATIENT COUNSELINGPatients undergoing any dental procedures which are potentially bacteremic should receive prophylactic antibiotictherapy.Indefinite therapy with low dose aspirin, unless contraindicated, is recommended for all patients with bioprostheticvalves, Indefinite anticoagulation therapy, unless contraindicated, is recommended for patients with thethromboembolism risk factors of moderate to severe atrial wall calcification or other

atrial wall abnormalities, atria]fibrillation, left ventricular dysfunction, a hypercoagulable condition, or a prior history of thromboembolic event orevents.Patients should use the identification card that contains patient and valve information for future reference.DIRECTIONS FOR USEThe Mitroflow valve is supplied sterile and non-pyrogenic in a 4% formaldehyde solution in a sealed container.The valve shall not be used if1) The expiration date has elapsed2) Either the high or low temperature indicators in the valve carton have been activated3) The valve container is damaged or has leaked4) The tamper evident seal is broken5) The bioprosthesis has been damaged6) The storage solution does not completely cover the valve. -6-For information regarding the return of any product, contact your local sales representative. A required "ReturnGoods Authorization" number and packaging instructions shall be provided. Explanted valves should be placed intoa suitable histo

logical fixative such as 10% formalin before being returned.Pre-Operative HandlingIt is recommended that the special obturators designed for use with the Mitroflow valve be used for valve sizeselection. The Mitroflow obturators will aid in choosing the appropriate size of valve to be used in the patient.OBTURATORS AND HANDLES FROM OTHER MANUFACTURERS ARE NOT SUITABLE FOR USEWITH THE MITROFLOW VALVE AND SHOULD NOT BE USED. The Mitroflow handles and obturators aresupplied NON-STERILE and must be cleaned and sterilized prior to each use. Do not use obturators if there aresigns of damage or aging such as cracking or crazing. Do not use obturators if printed text is not legible or theobturator appears to be damaged. Contact your sales representative for instrument replacement.All instrumentation must be wrapped for sterilization. Obturators must not be exposed to temperatures above 1370C(279°F). It is recommended that the handles and obturators be sterilized by

steam (autoclaving). Refer to sectionACCESSORY CLEANING AND STERILIZATION.Refer to the instrumentation instructions for use provided with the obturators and handles for further information.The Mitroflow obturators are designed to assist the surgeon in accurately sizing the aortic valvular annulus for usewith an appropriately sized Mitroflow valve in either supra-annular (Fig. 1) or intra-annular (Fig. 2) placement.The largest obturator dimension reflects the dimension of the valve sewing cuff in the relaxed position.The Mitroflow handle is used with the obturators for sizing, and with the Mitroflow valve holder for implantation.To attach the handle (Fig. 3), thread the handle into the obturator or valve holder with a clockwise rotation. Thevalve handle is separated by a counter clockwise rotation.Select a valve that will snugly fit into the aortic annulus for intra-annular placement or fit into the aortic root (Sinusof Valsalva) for supra-annular placement.

Care should be taken to prevent insertion of the obturator into the valvularannulus at an angle or to prevent selecting an obturator size that does not provide sufficient contact with the valvularannulus.Mitroflow valves should not be oversized. Mitroflow valves are for SINGLE USE ONLY. Selection of the propersize valve is the responsibility of the implanting surgeon.Each Mitroflow valve has a disposable valve holder attached at the time of manufacture. In addition, this holder ispositioned by a packaging insert to aid in removal of the valve from the container and storage solution.Device Preparation Prior to ImplantI. After selecting the appropriate size valve, obtain the correct valve size carton.2. Before removing the valve container, inspect the low and high temperature indicators. Do not use the valveif either the high or low temperature indicators have been activated (see section HOW SUPPLIED).3. Remove the valve container from the carton. Verify tha

t all carton and container labels match with respectto valve model, size, and serial number. IN THE EVENT OF ANY NON-MATCHINGINFORMATION, DO NOT USE THE VALVE. Contact your local sales representative to makearrangements for return or replacement.4. Carefully inspect the entire valve container and tamper-evident seal for damage. DO NOT USE THEVALVE IF THE VALVE CONTAINER IS DAMAGED OR IF THE SEAL IS BROKEN.5. Before opening the valve container, prepare THREE TALL rinse basins, each containing 300 ml of sterilephysiologic saline.6. Remove the tamper-evident seal and shrink-wrap from the valve container and unscrew the container lid.The contents of the jar are sterile and must be handled aseptically to prevent contamination. The outside ofthe jar is not sterile and must not enter the sterile field.7. To remove the valve from the container, insert the threaded area of the Mitroflow handle into the valveholder orifice. Thread the handle clockwise into the top of

the valve holder until tight (Fig. 4).8. Hold onto the jar and lift the packaging insert and valve out of the valve container (Fig. 5) and into thesterile field.BOTH THE VALVE AND 4% FORMALDEHYDE PACKAGING SOLUTION ARE STERILE. THEEXTERIOR OF THE CONTAINER IS NON-STERILE AND MUST NOT BE INTRODUCED INTO THESTERILE FIELD.ANY VALVE THAT IS DROPPED, DAMAGED, OR MISHANDLED IN ANYWAY SHOULD NOT BEUSED FOR IMPLANTATION. -7-CONTACTING THE VALVE WITH COTTON SWABS MAY LEAVE COTTON FIBERS ADHERING TOTHE PERICARDIAL LEAFLETS THAT COULD EMBOLIZE OR SERVE AS A NIDUS FOR THROMBUSDEVELOPMENT.METICULOUS CARE SHOULD BE GIVEN TO PREVENT CONTAMINATION OF THE VALVESTORAGE SOLUTION BY GLOVE POWDER,9. Grasp the packaging insert and slide the thin part of the holder through the slot in the packaging insert (Fig.6). Discard the packaging insert.10. Submerge the valve in the first rinse basin of sterile saline solution. It is recommended that a tall rinsebasin be used to prevent th

e handle from tipping over causing the valve to fall out of the basin.II. Verify that the information on the identification tag attached to the valve matches the correspondinginformation on the container, carton, and Patient Registration Form. Do not implant the valve if the data arenot identical.12. Detach the identification tag by cutting the suture attachment with scissors and removing all tag suturematerial (Fig. 7).13. By grasping the handle, gently agitate the valve for two minutes in the first rinse basin. Repeat the two-minute rinse in the second and third basins for a total rinse time of at least six minutes. DO NOT TOUCHTHE LEAFLETS OR SQUEEZE THE VALVE DURING RINSING.14. Allow the valve to remain in the third basin until required by the surgeon. DO NOT ALLOW THE TISSUETO DRY DURING THE HANDLING AND IMPLANTATION OF THE VALVE AS THIS COULDRENDER THE VALVE UNFIT FOR USE.Device ImplantationPrior to suturing the valve into the annulus, identify the di

rection of flow through the valve to ensure properorientation and subsequent function.Orient the valve so that the coronary ostia are not compromised.Do not handle the tissue portion of the valve with instruments.During implantation, frequently irrigate the valve tissue with sterile, physiologic saline to prevent dehydration.Operating Room (OR) personnel should hold the valve handle during the entire suturing of the sewing cuff.Do not use cutting edge suture needles, as these will damage the valve sewing ring.If interrupted sutures are used, care must be exercised to cut the sutures close to the knots and to ensure that suturetails do not come into contact with leaflet tissue.Extreme care should be exercised when placing sutures through the sewing ring to avoid possible laceration of thetissue. IF A VALVE IS DAMAGED, THE VALVE MUST BE EXPLANTED AND REPLACED. DO NOTATTEMPT TO REPAIR DAMAGE TO THE VALVE THAT MAY OCCUR DURING INSERTION.Looping or catching a su

ture around the commissural posts will interfere with valve clinical performance,Diligent attention is required by the surgeon while suturing the sewing ring to the annulus to avoid the occurrence ofperivalvular leaks.Following placement of the valve in the patient annulus, remove the handle-holder as a unit by severing the threeexposed holder retaining sutures on the right hand side of the knots (Fig. 8). Use a uniform motion to pull the handleaway from the implanted valve. Verify that all remaining suture material has been removed from the sewing cuff.After detaching the handle-holder unit, the holder and retaining sutures should be removed and discarded.The valve storage solution contains formaldehyde and may cause irritation of skin, eyes, nose, and throat. Do notbreathe storage solution vapor, Avoid prolonged skin contact with the formaldehyde solution, and if such contactoccurs, immediately flush area with copious amounts of water. In case of contact

with eyes, seek medical assistanceimmediately.It is beyond the scope of these instructions for use to instruct the surgeon in specific valve replacement surgicalprocedures. Reference should be made to pertinent scientific literature.PATIENT INFORMATIONIt is the responsibility of the implanting surgeon to inform the patient of the following symptoms that indicateimproper functioning of the replacement heart valve.A Mitroflow valve recipient should seek medical attention if they experience any of the following: angina, syncope,shortness of breath during exertion, orthopnea, paroxysmal nocturnal dyspnea, palpitations, ankle swelling, generalweight gain, shaking chills, fevers, night sweats, visual disturbance, unexpected petechiae, splinter hemorrhage, -8-flame hemorrhage, painful joints, painful spots in the toes, fingers, or soles of the feet, hemoptysis, hematuria orgastrointestinal disturbance.Magnetic Resonance Imaging (MRI)Non-clinical testing has demons

trated that the Mitroflow valve is MR Conditional. It can be scanned safely underthe following conditions:* Static magnetic field of 3.0 Tesla or less* Spatial gradient field of 525 Gauss/cm or less* Maximum whole-body-averaged specific absorption rate (SAR) of 1.5 W/kg for 20 minutes of scanning.In non-clinical testing, the Mitroflow valve produced a temperature rise of less than 0.80C at a maximum wholebody averaged specific absorption rate (SAR) of 1.5 W/kg for 20 minutes of MR scanning in a 1.5 Tesla, ModelSigna MR, GE Medical System, Milwaukee, WI, MR scanner.MR image quality may be compromised if the area of interest is in the exact same area or relatively close to theposition of the Mitroflow valve. Therefore, it may be necessary to optimize MR imaging parameters to compensatefor the presence of this implant.Patient Registration FormA Patient Registration Form is enclosed in each valve carton. The registration form must be completed and returnedas di

rected on the Patient Registration Form. Upon receipt of the form, an identification card will be prepared withpatient and valve information and sent to the patient.HOW SUPPLIEDThe Mitroflow valve is supplied sterile and non-pyrogenic in a sealed container, preserved in a 4% formaldehydestorage solution. Each valve is packaged individually in its own container. The valve packaging system is designedto facilitate convenient aseptic transfer of the valve to the sterile field.After implantation of the Mitroflow valve, the 4% formaldehyde storage solution should be disposed according tohospital procedure.Temperature Indicators to Indicate Shipping ConditionsEach shipping carton contains high and low temperature indicators (Fig. 9) to indicate whether extreme hot and/orcold temperatures have been encountered during shipping.The low temperature indicator contains a white background that will become dark-stained (Fig. 10) if the valve hasbeen exposed to excessive

cold temperatures.The high temperature indicator will turn BLACK (Fig. 10) if the product has been exposed to excessive heat.If either the high or low temperature indicator has been activated (Fig. 10), DO NOT USE THE VALVE.Immediately contact your local sales representative to make arrangements for return and replacement.STORAGE CONDITIONSThe Mitroflow valve must be stored at a temperature between +5°C and +25°C (41°F -770F). Avoid locationswhere extreme temperature fluctuations may occur; e.g. near steam, hot water pipes, air conditioning ducts, directsunlight, etc. REFRIGERATION IS NOT REQUIRED. Although refrigeration at 5°C (41°F) is acceptable, the riskof undetected freezing must be considered. FREEZING MAY SERIOUSLY DAMAGE THE VALVE ANDRENDER IT UNFIT FOR USE. DO NOT STORE UNDER REFRIGERATION UNLESS CONTINUOUSTEMPERATURE MONITORING IS MAINTAINED. Storage life of the bioprosthesis is 60 months from the dateof sterilization.ACCESSORY CLEANING AND STERIL

IZATIONThe Mitroflow handles and obturators are supplied NON-STERILE and must be cleaned and sterilized prior to eachuse. Do not use obturators if there are signs of damage or aging such as cracking or crazing. Do not use obturators ifprinted text is not legible or the obturator appears to be damaged. Contact your sales representative for instrumentreplacement.Cleaning and Disinfection Instructions for Mitroflow InstrumentationMITROFLOW INSTRUMENTS MAY BE DAMAGED BY STRONGLY ALKALINE OR STRONGLY ACIDICDETERGENTS AND SOLUTIONS, AND BY CHEMICALS CONTAINING KETONES OR CHLORINATEDSOLVENTS.It is recommended that instruments be reprocessed as soon as reasonably practical following use. The followingcleaning and disinfection methods are recommended for Mitroflow instrumentation: -9-Manual Cleaning and Disinfection1. Wipe instrument with wet, disposable sponge to remove gross soil.2. Rinse instrument in hot, running tap water for a minimum of 20 seconds to remove v

isible soil.3. Soak instruments in a bath of either (a) Wescodyne for five minutes, or (b) Terg-A-Zyme Enzymatic Cleaner(Alconox).4. Scrub instrument thoroughly with a soft bristle brush.5, Rinse instrument with de-ionized water for a minimum of 20 seconds to remove remaining soil and cleaningagent.Washer-Disinfector with Alkaline Detergent+After placing the instruments in the washer-disinfector, perform the following programmed cleaning cycles:Step Cycle Duration De-ionized Water CommentsI Pre-Wash 2 minutes 45 0C ± 5 0C Do not use detergents or additives.Drain when complete.2 Pre-Wash 2 minutes 45 0C + CC Do not use detergents or additives.Drain when complete.Follow instructions from manufacturer3 Wash I0 minutes 45 0C 5 0C ofwasher-disinfector for optimal mix ratioand concentration of alkaline detergent.Drain when complete.4 Rinse I minute 45 0C ± DC Do not use neutralizers in the rinse.Drain when complete.5 Rinse 2 minutes 91 0C ± 5 0C Do not use neutra

lizers in the rinse.Drain when complete.6 Dry 10 minutes --------- Forced Air at 91 QC+ Testing was conducted using HAMO T-21 washer-disinfector with HAMO Liquid 55 alkaline detergent (Deconex 22 LIQequivalent) utilizing mix ratio of 4 ml of detergent per liter of water in the wash.Washer-Disinfector with Enzyme Detergent*After placing the instruments in the washer-disinfector, perform the following programmed cleaning cycles:Step Cycle Duration Tap Water CommentsI Pre-Wash 5 minutes 50 0C 5 0C Do not use detergents or additives. Drain when complete.2 Pre-Wash 5 minutes 50 °C ± 5 0C Do not use detergents or additives. Drain when complete.Follow instructions from manufacturer of washer-3 Wash 10 minutes 60 QC ± 5 0C disinfector for optimal mix ratio and concentration ofenzyme detergent. Drain when complete.4 Rinse 5 minutes 90 DC ± 5 QC Drain when complete.5 Rinse 5 minutes 90 °C ± 5 °C Drain when complete.6 Cool 5 minutes Remove parts from washer-disinfecto

r and cool at roomtemperature.·Testing was conducted using Getinge/Castle washer- disinfector with Castle® Renuzyme enzyme detergent.Based on testing, it was determined that reusable instrumentation could be cleaned and disinfected a total of 100cycles using the above washer-disinfector based cleaning and disinfection methods, Note that changes to thesecleaning and disinfection methods may result in reduced instrument life cycles.'74' -10O-Sterilization Instructions for Mitroflow InstrumentationAll Mitroflow instrumentation must be cleaned and steam sterilized prior to initial use and each reuse. A maximumof two (2) handles and five (5) obturators may be sterilized in the Mitroflow Aortic Pericardial Heart ValveAccessory Tray; the accessory tray should not be used if it is damaged.Mitroflow instrumentation shall be wrapped and steam sterilized according to the following minimum parameters:Sterilization Instructions for Mitrollow InstrumentationContainer Wra

pped Instruments Wrapped Tray Wrapped TraywrpeTemperature 121 0C (250 0F) 121 0C (250 0F) 132 0C (270 0F) 134 0C (273 0F)Time 35 minutes 35 minutes 10 minutes 3 minutesCycle Pre-Vacuum Pre-Vacuum Pre-Vacuum Pre-VacuumFollow instructions provided by the manufacturer of the sterilization equipment and established hospital procedures.It is the responsibility of each institution to validate the process and to establish the efficacy of their procedure.VALVE SPECIFICATIONSMitroflow Aortic Pericardial Heart Valve -Model 12A* B* C* ~~~~~~~D*Sewing Ring **EffectiveModel Inside Diameter Outside Diameter Overall Height Width (Relaxed) Orifice Area(mm) (mm) (mm) (mm) (CM2)12A19 15.4 18.5 II1 2 1 1.612A2l 17.3 20.6 1 3 24 2.012A23 19.0 22.6 1 4 2 6 2.412A25 21.0 25.0 1 5 2 8 3.012A27 22.9 27.2 1 6 3 2 3.5;Dimensions illustr~ated in Fig. I -belo~w** In vitro data on fileWARRANTIESSORIN GROUP CANADA INC., MITROFLOW DIVISION WARRANTS THAT REASONABLE CARE WASUSED IN THE MAN

UFACTURE OF THIS DEVICE. SORIN GROUP CANADA INC., MITROFLOWDIVISION WARRANTS THAT THIS DEVICE WAS MANUFACTURED ACCORDING TO STRICTSPECIFICATIONS. NO OTHER WARRANTY, INCLUDING ANY WARRANTY OF MERCHANTABILITYOR FITNESS FOR PURPOSE, IS EITHER EXPRESSED OR IMPLIED SINCE HANDLING, STORAGE, ANDCLEANING OF THIS DEVICE AS WELL AS FACTORS RELATING TO THE PATIENT, DIAGNOSIS,TREATMENT, SURGICAL PROCEDURES AND OTHER MATTERS BEYOND SORIN GROUP CANADAINC., MITROFLOW DIVISION'S CONTROL DIRECTLY AFFECT THIS DEVICE AND THE RESULTSOBTAINED FROM ITS USE. SORIN GROUP CANADA INC., MITROFLOW DIVISION SHALL REPLACEANY PRODUCT THAT DOES NOT MEET THE TERMS OF THE WARRANTY CONTAINED HEREIN. THISLIMITED WARRANTY CONTAINS THE CUSTOMER'S EXCLUSIVE REMEDY. SORIN GROUP CANADAINC., MITROFLOW DIVISION SHALL NOT BE LIABLE FOR ANY INCIDENTAL, GENERAL, SPECIAL ORCONSEQUENTIAL DAMAGES ARISING FROM THE USE OF ITS PRODUCTS. SPECIFICALLYDISCLAIMED ARE ANY AND ALL WARRANTIES OR CONDITIONS TO THE E

XTENT THAT SUCH MAYBE IMPLIED UNDER THE PROVISIONS OF THE SALE OF GOODS ACT OF BRITISH COLUMBIA. NOREPRESENTATIVE OF THE COMPANY MAY MODIFY ANY OF THE FOREGOING AND THEPURCHASER AND/OR USER ACCEPTS THE PRODUCT SUBJECT TO ALL TERMS HEREIN STATED. -11-PRODUCT AVAILABILITYManufactured by:SORIN GROUP CANADA INC., MITROFLOW DIVISION5005 North Fraser WayBurnaby, B.C.CANADA V5J 5MITel: (604) 412-5650Fax: (604) 412-5690Distributed in U.S.A. by:CarboMedics Inc.14401 West 65th WayArvada, Colorado 80004 U.S.ATel: (800) 289-5759FIGURESFig. IFig. 230 -12 -! t~~~~~~-Fig. 3~,://Fig. 4iv~~?7~~~~9Fig. 53' -13 -Fi.Fi.Fi.Fig. 9 FFig.16 -14 -I i II III I ~---- -A -I IFig. 11'3'3 Bilyfl~~~~~~-L ~~14I~ (N m n IT IT 0 L Lf *O '0 C0 Co c~~~~~~~~~~~~~~~~~'~ C 0 J w- -i r) ~ i .0 E~~wEu 00.4L43 -~~~~3-Lu ~ ~CL 0 L E41 'J VC USI 0 E. o=. ."'~~~ -=' ~ 423 Eo~~~~~~ 4~ -1 ,, , '4-J ~ ~ ~ ~ ~ -L- 0:~~~~~~~~~~~ 0"0 0 I.-0 ~-u Q)�.,, o , -a'C '4-I=0 ~ ~. -~,,, m:3~~ 4i-=~0 rd 0 u 00

ID~.._=~ ~ ' ,, = -,, 0.=~ ~ $.Id ~ ~ ~ u o -t! ~ -a "IdF- d 0 cl a) -t LuLu 5 -4i 4-J 4.1 4-0/or~ -, kI.- --u).d o'E o .' ' ..~~Ea CD_o b -'a ·.../ _ -1+4i C Id L- a-w -c boY' ',, 0 ~~~~~~~~~~~~~~U ��E ~ ~ ~ ~ H4i UE~~~~~~~~~~~~d _0~~~~~~~~~~~~~~~~~~~!t di~ �'" -TFi- LW mn 2~' i:~zii!i -i 4-' ®.= �C i ...-~~ �C di ~~~~ ~~ di did)_ u-~~~~~~~~ CU ~ ~ ~ ~ ~ ~ ~ Cco ° ,od i .-t i ' i 0 M 0 ~ W s -C_ ._di4, _ yt d -di c0 4j- Eu '0 .w 0 VICU U L -I 4 -' Eu,' 0di CU di~ (d .-r-~ 0 00 d Idi diVdi &#xr000;&#xr000;L..Y. E75 41nCU U U L. 0 41 E CCv L. Idd L C -0 U &#xr000; W -o 0 &#xr000;di w0' m = u 41 4j rU-,C E 0 cm,LA E In i CU a, VIX0&#xr000; w 0 0~~~d 41C 0o:~~~~~~~~~~~~~~~~~~~~~~~~~~(L~~~~-·1 0 -+j E- ' C ,40.0~~~~~~~~ &#xr000;ELU~ ~~~~~~~~~~~~~ a', -, -,C E&#xr000; -~a ~, &#xr000; ~~s ...(3 &#xr000;&#xr000;X C0 u 4., EL~~~~~~' .. .2' o z �0-0Ou~~~~~~~.MU- c-7 E , o g :'r o- 0L. �0 2 E~~~0 i0 0di L ii Re -o .4 E

L 0 10tow ~ ~ ~ ~ ~ ~ ~ ~ ,J -ŽV cL L C � -�CoC) C o 2 wum 'O ii CŽ) 0 C� c E~~~~a .-C2 E 10 E m F-~ Co -I-~~~~~~~~~~~~~0C) .4C 01 0. di ii "E 0 � ~J o. rC 0-0 aCt3 L ~ O-C)2 d d 0)0 (i ·7E0 ) d'0 48-J&#x 000; c~~~ &#x 000; 0u Iv I' &#x 000; o.E -wI.- t ~o oZ-r~~~~~ 0 P -- ~~o C ~ 0) -~ ~o"J 4· 4-'L 0w 0 I- 0) C O CO00 ~LU U2 4 H .~ 0 L U)-- a) I- E .E 0 .E ._~ c~ .r- �._. 0: o �._~u ~ ~ ~~~ 'Cc ~ ~ -,o '~-0 r� 0~ ~ ~ ~~~~~~~~4~~~~~ 4, � U~~~~~~~~~~~·'r0 , 'r_-4j ~"r~o-"r t~~~~,a 0 -� ~~ ~ co 0~ -C !--0 ,~ ~~_~,~ � -o,c :'-d ' &#x 000;-g ~ rdcC'A -ror, ~ ~ ~ .2 o_ a) L- -C (LU~ ~ ~ ~ 4, z 4-1-W' 'E El i ' 0 P' ~ 'i~~~~~~C &#x 000;Rio 0 ~ ~ ~ ~ 9 Z 8 E
6 oI- sc 0AgE 0 75O" B00 0IwA 3
O07E I = o I0 0 c00 ., = m F:E 0 7.010-4E 0 0 0 00 oE 6 u0 00 X0cm noN Ou Q~~~~~~~~~U~~~~~~~~.0- o Ul -c~~~~~~-C .M 'U2L. Ž 0U U~~~4 E0 0U �o ci E0c7.. 0 c~O c~b 4ncaU 0 w C a'0, a� =- -I0 E I

CCWw , 007 C.Z--Si -L *E-5 L0 C '2 ~~~~~~~~a' CI'~- a oi-' Et� E~~~ Eu~ "a' .ac £04 i J t' -,rdO~~d0 0O23 2.E S.ESC0~44~~~~~~~~~~~~~~~~~~~~~~~~~~- La -U 4C 0-0- �~~E .00 .0-( E ac-0 ~ -(E~- -5 E0 (4( 24444 0)-v ( 92 -~ .y ~ = 0'I~~~~~~~~~~~~~~~~~~~~~~~~C 0~~~~~~~~~0L ~ ~ ~ ~ ~ ~~~L-v a 0 C) 'V0 C)~~~ 0 0 C~~ --C�C~~~~~C-c~~v2- C0--20 0~S 23' E ~ a-0 �O=~~C)C) 0 --ro0 C) c W- -C0C U0 L 44b C H -C~C = r0CiU M -O O00 0 ~ a flo ~-~E 2 a -Om -0� o0 M0o E =0 E0
o0 00 u0 = E� 0 00 0 0 0� 4-1 m 0 3
E .2E 0 1.0 Ep o 0 o -M 5 0 oT,0 p0�0 o02 -L
P E02 0M M .0 �u 0o 0 E0 000 m00E E.2 o 00 O"c C0 0 o 00 0 x0 w , o u 00 0 c0 00570 0 00 -, c , 0I 0 x 0 0EA= 0 -0 2 E 00 U " I= 0 0 C00E 0. c
- -0 2 "0 w 00 EE E0 E0 u E0E w 0:05 0 c " I x0&#x 000; 0 E 0 0 0 0
0 0o -E 00~~~~~~~o C0 M iH 0 44 4)0E d a0c04).2~~~~~~.. 14 =~~~~i 6 r-~~~~~~~~~~~~~ c6 ~ ~ ~ - 0Lw-a-m 0 ._ '.-~ uC 0-'-~ -v .o~o �0 (8 L E .~04)

4) a~ -( L- .-~~~~~~~~uu UUCD EU ~ ~ 4=(44- 0 CU~°~~~~~b0 tCC # --v Z -.,~E u .~0 ~00CL~*~-4. 0 ~ 0.o _ -.4o 0~~ 4~~~ '~~~ 4)0 E~~~= 4.. 1 0 14- 'L0 L Z 4_ 4u.~ oc ~ ~~~~~~~ 4~~, C-~~~~ ~~~ ~~-, V bO 40t1 E #Wu, 4) L,2 : C 4'..d C )4 E'~ 4)- -(.204 U, ( f C ) 0 -4)U 4) 0 ! o5 E 0J= 4- U C E -E 4)U 00~~~~~~~~~~~oE00o4.n0 L --~- '-& ~ 244 '~u4~~~~~4) 0,a) 00;,(4 0 b 0 0 )40 C -v3 0 E aA .L2 E'" * 0d= L C '.' CF: *d 4 )1 00;(4 E 'iii -V) 4 (# M(4 0 U (#4-# .. 00;.M ~ ~~~o I u -0w C ci �.0J 0 C; -LI.Q fta, .0, 0CL. 0 C0,bOO E 0 ..2 .2 x~~~~~~~~~)~.. C 0LI = LI 00) 0)4-I L 2 �LI'¶~~~ 022 0 a0, LI 0 W 0F- Zw 0) LI .2I Iz 3 zo o~ ~oI~o 02cE .10 50 o ~~U u UZ O¾ �C w it~~g C Africa~ ~ ~~£0OC30 00 0o S _~~~ O,O C'*OcE 3 0 b0 Cd�' 0 0 C-a-0--r n� �- co bOE o-�. ~ u 2 -VUE '. �t! E£0on 0 E}-~~C5~ .-~0 .Eso cC-COm 0 , 0 C75 -c E O'7 0 '0 CE _ Cau 0u .:'0' r 0 w-5c GO E 0- E C)cm 0 C 0 ) 4iC -C fuE i

r L Cd .u p~o C 0p '(9 2~ Ut"O b -o £0L~~~~~ 0 0 ~~~00-�a- 0 EQ -o~~~~~~4-v~0 �00EUd ...0 O ~ '~ l eU 1-' 4) In C)z ~ ~ .-E~C 4-j =-2 _ C0~~~~2 E �0 ~4-' �%1 dO) �a LU ~ ~ ~ ~ ~ ~ MCi � C udL~~~0 0~~- ~ -l1~~~ Lu ~~Lzi 4- 4~~ g~o -c oD' ~~. -v LCd0 0-0 C) toW
;
inljjji YX
lI W40 o)p c 0E 0- o o00 L 0, -M 0 we3:0 0 _0oz 0 0 u Ec 0 0000 i

x
o E 80E -20 0 -6o 0mo o m0 0 U00 (3cZ 00 0 0F E Cc 0 u 0U X 0000E 0-F -0 E037 -0 F ucl
LLJ 0 .0
o 0DoZ�. FLI. Li y 0 � 0Ln0 ..00~~~~~~~~~~~~~~~~~~Z E-F4,~~~~~~~~~~~~~~~~-o(c0 0-c~~~~~~~~~(C~~~~~~~~~~~~~~~~~~4~~~~~~~ z0~SLiii1~ ~ ~ zp'!~; ~~ii,~ ~ ~ ~~(IF0z0(ALii~~~~~~~~~~~~~~~~~~~ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~i ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ '6~ ~ ~ ~ ~~~~~~~~~~C z0U)bOCC Cr LCtU4,-c -ca ., ,(4 bCŽo'I-oo '4Sb C-)�-o% 0- � s, (40 E d-c ' a, *vo4-a bd SBt Ž2 2 *0 o ES -: -4-,0]-oS0t0 0 U -n0) �%0 04L-C UU,0'  C u -